Dyadic Announces Third Quarter 2024 Financial Results and Strategic Progress Across Key Markets
12 nov. 2024 16h05 HE
|
Dyadic International, Inc.
Highlights Revenue Milestones and Expands Alternative Protein & Pharmaceutical Partnerships with Dapibus™ & C1 Technology Platforms Alternative Proteins Demonstrated substantial revenue...
Dyadic to Report Third Quarter 2024 Financial Results on Tuesday, November 12, 2024
04 nov. 2024 16h30 HE
|
Dyadic International, Inc.
JUPITER, Fla., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a biotechnology company focused on the efficient...
Dyadic Expands Global Presence with Participation in Key Industry Events
09 oct. 2024 08h00 HE
|
Dyadic International, Inc.
JUPITER, Fla., Oct. 09, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic” or the “Company”) (NASDAQ: DYAI), a biotechnology company focused on the large-scale, efficient manufacturing of...
Dyadic Provides Alternative Proteins Business Update and Announces Attendance at Bioprocess International Conference
23 sept. 2024 09h50 HE
|
Dyadic International, Inc.
JUPITER, Fla., Sept. 23, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a biotechnology company focused on the efficient,...
Dyadic Announces Second Quarter 2024 Financial Results and Highlights Recent Company Progress
13 août 2024 16h05 HE
|
Dyadic International, Inc.
Alternative Proteins Entered into a development and commercialization partnership for the sale of animal-free recombinant albumin products with Proliant Health and BiologicalsEntered into a joint...
Dyadic to Report Second Quarter 2024 Financial Results on Tuesday, August 13, 2024
30 juil. 2024 16h00 HE
|
Dyadic International, Inc.
JUPITER, Fla., July 30, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a biotechnology company focused on the efficient...
Dyadic International, Inc. and Proliant Health and Biologicals announce Recombinant Albumin Development and Commercialization Partnership
28 juin 2024 08h30 HE
|
Dyadic International, Inc.
JUPITER, Fla., June 28, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”) (NASDAQ: DYAI), announced today that they have entered into a development and commercialization partnership...
Dyadic to Attend Industry Events in June
30 mai 2024 16h30 HE
|
Dyadic International, Inc.
JUPITER, Fla., May 30, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a biotechnology company focused on the efficient large-scale manufacture of...
Dyadic Announces First Quarter 2024 Financial Results and Highlights Recent Company Progress
14 mai 2024 16h00 HE
|
Dyadic International, Inc.
Human Health Sector Final Clinical Study Report has been issued for the First-In-Human Phase 1 clinical trial demonstrating safety and antibody response for DYAI-100, a recombinant...
Dyadic to Attend Industry and Investor Events in May
08 mai 2024 08h30 HE
|
Dyadic International, Inc.
JUPITER, Fla., May 08, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial...